Sungho Bea
Overview
Explore the profile of Sungho Bea including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
61
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Lee H, Bea S, Kim J, Jeong H, Jang S, Son H, et al.
Public Health
. 2024 Mar;
229:167-175.
PMID: 38452561
Objectives: The clinical importance of adhering to the regimen in tuberculosis patients has been widely investigated, but most studies were conducted in controlled settings and in limited populations. We aimed...
12.
Bea S, Yoon D, Jeong H, Jung J, Park S, Jeon J, et al.
Yonsei Med J
. 2024 Jan;
65(2):120-128.
PMID: 38288652
Purpose: Following the withdrawal of propacetamol in Europe owing to safety issues, the regulatory authority of South Korea requested a post-marketing surveillance study to investigate its safety profile. Materials And...
13.
Bea S, Lee H, Park S, Cho Y, Choi W, Bykov K, et al.
Clin Pharmacol Ther
. 2024 Jan;
115(5):1132-1140.
PMID: 38284421
Concomitant use of sodium glucose cotransporter-2 inhibitors (SGLT-2i) and overactive bladder (OAB) drugs potentially poses a risk of urinary tract infections (UTIs) due to the urinary retention of highly concentrated...
14.
Kim S, Bea S, Choe S, Choi N, Shin J
Eur J Clin Pharmacol
. 2024 Jan;
80(3):445-453.
PMID: 38212538
Purpose: Owing to adverse event following immunization (AEFI) related to autoimmune disorders and coronavirus disease 2019 (COVID-19) vaccines sharing common biological mechanisms, identifying the risk of AEFIs associated with COVID-19...
15.
Outcomes of SGLT-2i and GLP-1RA Therapy Among Patients With Type 2 Diabetes and Varying NAFLD Status
Bea S, Jeong H, Filion K, Yu O, Cho Y, Lee B, et al.
JAMA Netw Open
. 2023 Dec;
6(12):e2349856.
PMID: 38153732
Importance: Nonalcoholic fatty liver disease (NAFLD) is a cardiovascular risk factor, but whether sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) are associated with reduced cardiovascular risk in...
16.
Cho Y, Bea S, Bae J, Kim D, Lee J, Shin J
Expert Opin Drug Saf
. 2023 Dec;
23(8):1027-1033.
PMID: 38112005
Background: Finasteride is commonly prescribed for androgenic alopecia and benign prostatic hyperplasia. However, concerns regarding its safety have been growing as cases of cognitive dysfunction have been reported. Methods: A...
17.
Chen J, Shin J, Shantakumar S, Bea S, Ye B, Lee D, et al.
Infect Dis Ther
. 2023 Dec;
12(12):2771-2790.
PMID: 38085494
Introduction: To estimate herpes zoster (HZ) incidence rate (IR) and economic burden in individuals with immunocompromised conditions and autoimmune diseases (IC/AID) in the Republic of Korea (ROK). Methods: The nationwide...
18.
Ko H, Bea S, Jeong H, Park S, Cho Y, Kong S, et al.
JAMA Netw Open
. 2023 Sep;
6(9):e2335797.
PMID: 37751205
Importance: Postmenopausal individuals with type 2 diabetes are susceptible to fractures due to the interaction of elevated blood glucose levels and a deficiency of the hormone estrogen. Despite continued concerns...
19.
Bea S, Son H, Bae J, Cho S, Shin J, Cho Y
Diabetes Obes Metab
. 2023 Sep;
26(1):108-117.
PMID: 37735822
Aims: To determine the potential association between the use of either glucagon-like peptide-1 receptor agonists (GLP-1RAs) or dipeptidyl peptidase-4 (DPP-4) inhibitors, and the risk of thyroid cancer in individuals with...
20.
Park S, Jeong H, Bea S, Yu O, Cho Y, Chan You S, et al.
Diabetes Obes Metab
. 2023 Jul;
25(11):3248-3258.
PMID: 37503763
Aim: To assess the risk of amputation associated with sodium-glucose co-transporter-2 inhibitors (SGLT2is) among patients with type 2 diabetes, across categories of baseline cardiovascular disease (CVD) and diuretic use (DU)....